PUBLICATIONS Archives - Page 2 of 3

Graviton

0

PUBLICATIONS

June 1, 2016

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 (Poster and Poster Discussion Sessions at the ASCO Meeting on Sunday June 5, 2016, Abstract #2512, Board #212)

Graviton

0

PUBLICATIONS

April 19, 2016

FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS-mutant NSCLC patients in a phase I study (Poster Presentation at AACR Meeting on Monday Apr 18, 2016 1:00 PM, Abstract number LB-214)

Graviton

0

PUBLICATIONS

April 19, 2016

Preclinical studies characterize tumor type sensitivity to FASN inhibition and the mechanism and efficacy of novel drug combinations with TVB-2640 (Poster Presentation at AACR Meeting on Wednesday, April 20, 2016, Abstract number 4743)

Graviton

0

PUBLICATIONS

March 24, 2016

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640” presented by Dr. Manish Patel at the Targeted Anticancer Therapies (TAT) Congress on Wednesday March 23, 2016 at 12 noon EDT

Graviton

0

PUBLICATIONS

March 2, 2016

Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement (Abstract #1022 and Short Presentation at Keystone Symposium, “New Frontiers in Understanding Tumor Metabolism” February 21-25, 2016, Banff, Alberta, Canada)

Graviton

0

PUBLICATIONS

November 8, 2015

FASN inhibition studies in preclinical tumor models identify biomarkers that align with in vitro and in vivo sensitivity to TVB-2640 (Poster Presentation at AACR-NCI-EORTC meeting on Sunday Nov 8, 2015)

Graviton

0

PUBLICATIONS

November 7, 2015

Biomarker Analyses from Dose Escalation Phase of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients (Poster presented at AACR-NCI-EORTC Meeting on Saturday, Nov 7, 2015)

Graviton

0

PUBLICATIONS

October 27, 2015

A First-In-Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor TVB-2640 Results of Dose Escalation in Mono and Combination and Evidence of Preliminary Activity (Poster presentation at AACR-NCI-EORTC Meeting Session A on Friday Nov 6, 2015 12:15 PM – 3:15 PM)

Graviton 0

0

PUBLICATIONS

October 12, 2015

ESMO 2015 Oral Presentation: A First-In-Human Study of the First-In- Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640, as Monotherapy or in Combination

Graviton

0

PUBLICATIONS

July 17, 2015

Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression (Paper, EBioMedicine)

PUBLICATIONS

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 (Poster and Poster Discussion Sessions at the ASCO Meeting on Sunday June 5, 2016, Abstract #2512, Board #212)

FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS-mutant NSCLC patients in a phase I study (Poster Presentation at AACR Meeting on Monday Apr 18, 2016 1:00 PM, Abstract number LB-214)

Preclinical studies characterize tumor type sensitivity to FASN inhibition and the mechanism and efficacy of novel drug combinations with TVB-2640 (Poster Presentation at AACR Meeting on Wednesday, April 20, 2016, Abstract number 4743)

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640” presented by Dr. Manish Patel at the Targeted Anticancer Therapies (TAT) Congress on Wednesday March 23, 2016 at 12 noon EDT

FASN inhibition studies in preclinical tumor models identify biomarkers that align with in vitro and in vivo sensitivity to TVB-2640 (Poster Presentation at AACR-NCI-EORTC meeting on Sunday Nov 8, 2015)

Biomarker Analyses from Dose Escalation Phase of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients (Poster presented at AACR-NCI-EORTC Meeting on Saturday, Nov 7, 2015)

A First-In-Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor TVB-2640 Results of Dose Escalation in Mono and Combination and Evidence of Preliminary Activity (Poster presentation at AACR-NCI-EORTC Meeting Session A on Friday Nov 6, 2015 12:15 PM – 3:15 PM)

ESMO 2015 Oral Presentation: A First-In-Human Study of the First-In- Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640, as Monotherapy or in Combination

Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression (Paper, EBioMedicine)

Site Map

Contact Us